Evidence map›Paper›PMID 35696077›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

iProtGly-SS: A Tool to Accurately Predict Protein Glycation Site Using Structural-Based Features.

Iman Dehzangi, Alok Sharma, Swakkhar Shatabda

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. DOTAD: A Database of Therapeutic Antibody Developability.Interdisciplinary sciences, computational life sciences · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Iman DehzangiDepartment of Computer Science, Rutgers University, Camden, NJ, USA. i.dehzangi@rutgers.edu.
Alok SharmaInstitute for Integrated and Intelligent Systems, Griffith University, Brisbane, QLD, Australia. alokanand.sharma@riken.jp.
Swakkhar ShatabdaDepartment of Computer Science and Engineering, United International University, Dhaka, Bangladesh. swakkhar@cse.uiu.ac.bd.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Posttranslational modification (PTM) is an important biological mechanism to promote functional diversity among the proteins. So far, a wide range of PTMs has been identified. Among them, glycation is considered as one of the most important PTMs. Glycation is associated with different neurological disorders including Parkinson and Alzheimer. It is also shown to be responsible for different diseases, including vascular complications of diabetes mellitus. Despite all the efforts have been made so far, the prediction performance of glycation sites using computational methods remains limited. Here we present a newly developed machine learning tool called iProtGly-SS that utilizes sequential and structural information as well as Support Vector Machine (SVM) classifier to enhance lysine glycation site prediction accuracy. The performance of iProtGly-SS was investigated using the three most popular benchmarks used for this task. Our results demonstrate that iProtGly-SS is able to achieve 81.61%, 93.62%, and 92.95% prediction accuracies on these benchmarks, which are significantly better than those results reported in the previous studies. iProtGly-SS is implemented as a web-based tool which is publicly available at http://brl.uiu.ac.bd/iprotgly-ss/ .

Indexed as

Computational BiologyProteinsGlycosylationLysineProtein Processing, Post-TranslationalSupport Vector MachineLysineProteinsEvolutionary featuresFeature selectionPosttranslational modificationProtein glycationStructural featuresSupport vector machine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.